;PMID: 10934946
;source_file_2877.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..126] = [t:44..126]
;2)sentence:[e:127..148] = [t:127..148]
;3)section:[e:152..193] = [t:152..193]
;4)section:[e:197..290] = [t:197..290]
;5)sentence:[e:294..304] = [t:294..304]
;6)sentence:[e:305..431] = [t:305..431]
;7)sentence:[e:432..445] = [t:432..445]
;8)sentence:[e:446..579] = [t:446..579]
;9)sentence:[e:580..662] = [t:580..662]
;10)sentence:[e:663..671] = [t:663..671]
;11)sentence:[e:672..853] = [t:672..853]
;12)sentence:[e:854..930] = [t:854..930]
;13)sentence:[e:931..1118] = [t:931..1118]
;14)sentence:[e:1119..1130] = [t:1119..1130]
;15)sentence:[e:1131..1253] = [t:1131..1253]
;16)sentence:[e:1254..1354] = [t:1254..1354]
;17)section:[e:1358..1403] = [t:1358..1403]

;section 0 Span:0..38
;Acta Cytol.  2000 Jul-Aug;44(4):543-6.
(SEC
  (FRAG (NNP:[0..4] Acta) (NNP:[5..10] Cytol) (.:[10..11] .) (CD:[13..17] 2000)
        (NNP:[18..25] Jul-Aug) (::[25..26] ;) (CD:[26..28] 44)
        (-LRB-:[28..29] -LRB-) (CD:[29..30] 4) (-RRB-:[30..31] -RRB-)
        (::[31..32] :) (CD:[32..37] 543-6) (.:[37..38] .)))

;sentence 1 Span:44..126
;Bull's eye (target) inclusions in neoplastic cells in malignant serous 
;effusions.
;[78..94]:malignancy-type:"neoplastic cells"
(SENT
  (NP-HLN
    (NP
      (NML
        (NML
          (NP (NN:[44..48] Bull) (POS:[48..50] 's))
          (NN:[51..54] eye))
        (NML (-LRB-:[55..56] -LRB-) (NN:[56..62] target) (-RRB-:[62..63] -RRB-)))
      (NNS:[64..74] inclusions))
    (PP-LOC (IN:[75..77] in)
      (NP (JJ:[78..88] neoplastic) (NNS:[89..94] cells)))
    (PP-LOC (IN:[95..97] in)
      (NP (JJ:[98..107] malignant) (JJ:[108..114] serous)
          (NNS:[116..125] effusions)))
    (.:[125..126] .)))

;sentence 2 Span:127..148
;A study of 289 cases.
(SENT
  (NP
    (NP (DT:[127..128] A) (NN:[129..134] study))
    (PP (IN:[135..137] of)
      (NP (CD:[138..141] 289) (NNS:[142..147] cases)))
    (.:[147..148] .)))

;section 3 Span:152..193
;Kumar PV, Eqbali S, Monabati A, Talei AR.
(SEC
  (FRAG (NNP:[152..157] Kumar) (NNP:[158..160] PV) (,:[160..161] ,)
        (NNP:[162..168] Eqbali) (NNP:[169..170] S) (,:[170..171] ,)
        (NNP:[172..180] Monabati) (NNP:[181..182] A) (,:[182..183] ,)
        (NNP:[184..189] Talei) (NNP:[190..192] AR) (.:[192..193] .)))

;section 4 Span:197..290
;Department of Pathology, Shiraz Medical School, Shiraz University of Medical 
;Sciences, Iran.
(SEC
  (FRAG (NNP:[197..207] Department) (IN:[208..210] of)
        (NNP:[211..220] Pathology) (,:[220..221] ,) (NNP:[222..228] Shiraz)
        (NNP:[229..236] Medical) (NNP:[237..243] School) (,:[243..244] ,)
        (NNP:[245..251] Shiraz) (NNP:[252..262] University) (IN:[263..265] of)
        (NNP:[266..273] Medical) (NNP:[275..283] Sciences) (,:[283..284] ,)
        (NNP:[285..289] Iran) (.:[289..290] .)))

;sentence 5 Span:294..304
;OBJECTIVE:
(SENT
  (NP (NN:[294..303] OBJECTIVE) (::[303..304] :)))

;sentence 6 Span:305..431
;To study the prevalence and significance of bull's eye (target)  inclusions
;in neoplastic cells in malignant serous effusions.
;[384..400]:malignancy-type:"neoplastic cells"
(SENT
  (S
    (NP-SBJ (-NONE-:[305..305] *))
    (VP (TO:[305..307] To)
      (VP (VB:[308..313] study)
        (NP
          (NP (DT:[314..317] the) (NN:[318..328] prevalence) (CC:[329..332] and)
              (NN:[333..345] significance))
          (PP (IN:[346..348] of)
            (NP
              (NML
                (NML
                  (NP (NN:[349..353] bull) (POS:[353..355] 's))
                  (NN:[356..359] eye))
                (NML (-LRB-:[360..361] -LRB-) (NN:[361..367] target)
                     (-RRB-:[367..368] -RRB-)))
              (NNS:[370..380] inclusions))))
        (PP (IN:[381..383] in)
          (NP (JJ:[384..394] neoplastic) (NNS:[395..400] cells)))
        (PP (IN:[401..403] in)
          (NP (JJ:[404..413] malignant) (JJ:[414..420] serous)
              (NNS:[421..430] effusions)))))
    (.:[430..431] .)))

;sentence 7 Span:432..445
;STUDY DESIGN:
(SENT
  (NP (NN:[432..437] STUDY) (NN:[438..444] DESIGN) (::[444..445] :)))

;sentence 8 Span:446..579
;We  reviewed malignant pleural, peritoneal and pericardial effusions from 289
; patients who had proven cancer at known primary sites.
(SENT
  (S
    (NP-SBJ (PRP:[446..448] We))
    (VP (VBD:[450..458] reviewed)
      (NP
        (NP
          (NP
            (ADJP-1 (JJ:[459..468] malignant))
            (JJ:[469..476] pleural)
            (NML-2 (-NONE-:[476..476] *P*)))
          (,:[476..477] ,)
          (NP
            (ADJP-1 (-NONE-:[477..477] *P*))
            (JJ:[478..488] peritoneal)
            (NML-2 (-NONE-:[488..488] *P*)))
          (CC:[489..492] and)
          (NP
            (ADJP-1 (-NONE-:[492..492] *P*))
            (JJ:[493..504] pericardial)
            (NML-2 (NNS:[505..514] effusions))))
        (PP (IN:[515..519] from)
          (NP
            (NP (CD:[520..523] 289) (NNS:[525..533] patients))
            (SBAR
              (WHNP-3 (WP:[534..537] who))
              (S
                (NP-SBJ-3 (-NONE-:[537..537] *T*))
                (VP (VBD:[538..541] had)
                  (NP (VBN:[542..548] proven) (NN:[549..555] cancer))
                  (PP-LOC (IN:[556..558] at)
                    (NP (VBN:[559..564] known) (JJ:[565..572] primary)
                        (NNS:[573..578] sites))))))))))
    (.:[578..579] .)))

;sentence 9 Span:580..662
;The ages of the patients  ranged from 5 to 72 years; 166 were male and 123
;female.
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[580..583] The) (NNS:[584..588] ages))
        (PP (IN:[589..591] of)
          (NP (DT:[592..595] the) (NNS:[596..604] patients))))
      (VP (VBD:[606..612] ranged)
        (PP (IN:[613..617] from)
          (NP
            (QP (CD:[618..619] 5) (TO:[620..622] to) (CD:[623..625] 72))
            (NNS:[626..631] years)))))
    (::[631..632] ;)
    (S
      (S
        (NP-SBJ=1 (CD:[633..636] 166))
        (VP (VBD:[637..641] were)
          (ADJP-PRD=2 (JJ:[642..646] male))))
      (CC:[647..650] and)
      (S
        (NP-SBJ=1 (CD:[651..654] 123))
        (ADJP-PRD=2 (JJ:[655..661] female))))
    (.:[661..662] .)))

;sentence 10 Span:663..671
;RESULTS:
(SENT
  (NP (NNS:[663..670] RESULTS) (::[670..671] :)))

;sentence 11 Span:672..853
;Bull's eye  inclusions are an uncommon finding and appeared in only 13 cases
;of metastatic  adenocarcinoma of the breast, stomach, colon, lung, ovary,
;pancreas and urinary  bladder.
;[752..762]:malignancy-clinical-stage:"metastatic"
;[764..778]...[836..852]:malignancy-type:"adenocarcinoma"..."urinary 
;bladder"
;[764..778]...[823..831]:malignancy-type:"adenocarcinoma"..."pancreas"
;[764..778]...[816..821]:malignancy-type:"adenocarcinoma"..."ovary"
;[764..778]...[810..814]:malignancy-type:"adenocarcinoma"..."lung"
;[764..778]...[803..808]:malignancy-type:"adenocarcinoma"..."colon"
;[764..778]...[794..801]:malignancy-type:"adenocarcinoma"..."stomach"
;[764..778]...[786..792]:malignancy-type:"adenocarcinoma"..."breast"
(SENT
  (S
    (NP-SBJ
      (NML
        (NP (NN:[672..676] Bull) (POS:[676..678] 's))
        (NN:[679..682] eye))
      (NNS:[684..694] inclusions))
    (VP
      (VP (VBP:[695..698] are)
        (NP-PRD (DT:[699..701] an) (JJ:[702..710] uncommon)
                (NN:[711..718] finding)))
      (CC:[719..722] and)
      (VP (VBD:[723..731] appeared)
        (PP (IN:[732..734] in)
          (NP
            (NP (RB:[735..739] only) (CD:[740..742] 13) (NNS:[743..748] cases))
            (PP (IN:[749..751] of)
              (NP
                (NP (JJ:[752..762] metastatic) (NN:[764..778] adenocarcinoma))
                (PP (IN:[779..781] of)
                  (NP
                    (NP (DT:[782..785] the) (NN:[786..792] breast))
                    (,:[792..793] ,)
                    (NP (NN:[794..801] stomach))
                    (,:[801..802] ,)
                    (NP (NN:[803..808] colon))
                    (,:[808..809] ,)
                    (NP (NN:[810..814] lung))
                    (,:[814..815] ,)
                    (NP (NN:[816..821] ovary))
                    (,:[821..822] ,)
                    (NP (NN:[823..831] pancreas))
                    (CC:[832..835] and)
                    (NP (JJ:[836..843] urinary) (NN:[845..852] bladder))))))))))
    (.:[852..853] .)))

;sentence 12 Span:854..930
;They were positively stained with periodic acid-Schiff stain with  diastase.
;[921..929]:gene-protein:"diastase"
(SENT
  (S
    (NP-SBJ-1 (PRP:[854..858] They))
    (VP (VBD:[859..863] were)
      (ADVP (RB:[864..874] positively))
      (VP (VBN:[875..882] stained)
        (NP-1 (-NONE-:[882..882] *))
        (PP-MNR (IN:[883..887] with)
          (NP
            (NP
              (NML
                (NML (JJ:[888..896] periodic) (NN:[897..901] acid))
                (HYPH:[901..902] -) (NNP:[902..908] Schiff))
              (NN:[909..914] stain))
            (PP (IN:[915..919] with)
              (NP (NN:[921..929] diastase)))))))
    (.:[929..930] .)))

;sentence 13 Span:931..1118
;The inclusions were not seen in cells of nonadenocarcinomatous  neoplasms,
;such as squamous cell carcinoma, oat cell (small cell) carcinoma, 
;neuroblastoma, lymphoma and germ cell tumors.
;[972..1004]:malignancy-type:"nonadenocarcinomatous  neoplasms"
;[1014..1037]:malignancy-type:"squamous cell carcinoma"
;[1039..1070]:malignancy-type:"oat cell (small cell) carcinoma"
;[1073..1086]:malignancy-type:"neuroblastoma"
;[1088..1096]:malignancy-type:"lymphoma"
;[1101..1117]:malignancy-type:"germ cell tumors"
(SENT
  (S
    (NP-SBJ-1 (DT:[931..934] The) (NNS:[935..945] inclusions))
    (VP (VBD:[946..950] were) (RB:[951..954] not)
      (VP (VBN:[955..959] seen)
        (NP-1 (-NONE-:[959..959] *))
        (PP-LOC (IN:[960..962] in)
          (NP
            (NP (NNS:[963..968] cells))
            (PP (IN:[969..971] of)
              (NP
                (NP (JJ:[972..993] nonadenocarcinomatous)
                    (NNS:[995..1004] neoplasms))
                (,:[1004..1005] ,)
                (PP (JJ:[1006..1010] such) (IN:[1011..1013] as)
                  (NP
                    (NP (JJ:[1014..1022] squamous) (NN:[1023..1027] cell)
                        (NN:[1028..1037] carcinoma))
                    (,:[1037..1038] ,)
                    (NP
                      (NML (NN:[1039..1042] oat) (NN:[1043..1047] cell))
                      (PRN (-LRB-:[1048..1049] -LRB-)
                        (NP (JJ:[1049..1054] small) (NN:[1055..1059] cell))
                        (-RRB-:[1059..1060] -RRB-))
                      (NN:[1061..1070] carcinoma))
                    (,:[1070..1071] ,)
                    (NP (NN:[1073..1086] neuroblastoma))
                    (,:[1086..1087] ,)
                    (NP (NN:[1088..1096] lymphoma))
                    (CC:[1097..1100] and)
                    (NP (NN:[1101..1105] germ) (NN:[1106..1110] cell)
                        (NNS:[1111..1117] tumors))))))))))
    (.:[1117..1118] .)))

;sentence 14 Span:1119..1130
;CONCLUSION:
(SENT
  (NP (NN:[1119..1129] CONCLUSION) (::[1129..1130] :)))

;sentence 15 Span:1131..1253
;Bull's eye inclusions  are found in about 5% of malignant serous effusions
;containing cells of  metastatic adenocarcinoma.
;[1227..1237]:malignancy-clinical-stage:"metastatic"
;[1238..1252]:malignancy-type:"adenocarcinoma"
(SENT
  (S
    (NP-SBJ-1
      (NML
        (NP (NN:[1131..1135] Bull) (POS:[1135..1137] 's))
        (NN:[1138..1141] eye))
      (NNS:[1142..1152] inclusions))
    (VP (VBP:[1154..1157] are)
      (VP (VBN:[1158..1163] found)
        (NP-1 (-NONE-:[1163..1163] *))
        (PP-LOC (IN:[1164..1166] in)
          (NP
            (NP
              (QP (RB:[1167..1172] about) (CD:[1173..1174] 5))
              (NN:[1174..1175] %))
            (PP (IN:[1176..1178] of)
              (NP
                (NP (JJ:[1179..1188] malignant) (JJ:[1189..1195] serous)
                    (NNS:[1196..1205] effusions))
                (VP (VBG:[1206..1216] containing)
                  (NP
                    (NP (NNS:[1217..1222] cells))
                    (PP (IN:[1223..1225] of)
                      (NP (JJ:[1227..1237] metastatic)
                          (NN:[1238..1252] adenocarcinoma)))))))))))
    (.:[1252..1253] .)))

;sentence 16 Span:1254..1354
;The primary site of an adenocarcinoma cannot be  deduced on the basis of the
;presence of inclusions.
;[1277..1291]:malignancy-type:"adenocarcinoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1254..1257] The) (JJ:[1258..1265] primary) (NN:[1266..1270] site))
      (PP (IN:[1271..1273] of)
        (NP (DT:[1274..1276] an) (NN:[1277..1291] adenocarcinoma))))
    (VP (MD:[1292..1298] cannot)
      (VP (VB:[1299..1301] be)
        (VP (VBN:[1303..1310] deduced)
          (NP-1 (-NONE-:[1310..1310] *))
          (PP (IN:[1311..1313] on)
            (NP
              (NP (DT:[1314..1317] the) (NN:[1318..1323] basis))
              (PP (IN:[1324..1326] of)
                (NP
                  (NP (DT:[1327..1330] the) (NN:[1331..1339] presence))
                  (PP (IN:[1340..1342] of)
                    (NP (NNS:[1343..1353] inclusions))))))))))
    (.:[1353..1354] .)))

;section 17 Span:1358..1403
;PMID: 10934946 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1358..1362] PMID) (::[1362..1363] :) (CD:[1364..1372] 10934946)
        (NN:[1373..1374] -LSB-) (NNP:[1374..1380] PubMed) (::[1381..1382] -)
        (NN:[1383..1390] indexed) (IN:[1391..1394] for)
        (NNP:[1395..1402] MEDLINE) (-RRB-:[1402..1403] -RSB-)))
